Weight Loss Ad Sparks Controversy: "Don't Promote Obesity, It's A lifestyle Disease," Say Experts
Rise of the weight loss market
With the launch of Mounjaro and Wegovy (weight loss drugs) in India, the biological and genetic components of obesity have gained evident recognition. The portrayal of obesity as solely a medical condition further overshadows the importance of preventive measures and lifestyle modifications. This marketing shift also raises questions about the commercialisation of health issues and the profit-driven motives of pharmaceutical giants.
Lifestyle modifications over weight loss drugs: The choice matters
The reliance on weight loss medications can fuel a misconception that obesity can be resolved without addressing the underlying lifestyle issues.
Obesity management is more than just shedding kilos. Obesity is a common risk factor for several serious health conditions like diabetes, heart disease, hypertension, fatty liver and others. Obesity management must focus on a diverse approach that improves overall health, reducing the risk of related conditions rather than depending on temporary fixes.
"Dependence on weight loss drugs is not the healthiest way to lose weight. Also, using weight loss drugs is not an easy approach as these medications are strictly available on prescription. There is a classical criterion, whether you have diabetes, arthritis or if your BMI is more than 30. "
"These weight loss drugs are not a replacement for lifestyle choices. One should primarily focus on preventing obesity by restricting fat and sugar content and exercising regularly," said Dr. Ashish Gautam, Senior Robotic, Bariatric, and Gastrointestinal Surgeon at Max Hospital.
On the other hand, Dr. Vaibhav Singhal, Consultant - Endocrinology at Max Hospital suggests that a combination of both might help. "Obesity can be genetic or a result of some health condition. A combination of both, weight loss medication nd healthy lifestyle choices might help achieve effective results, especially when diet and exercise become ineffective or when the BMI is severely high."
"These drugs do have side effects like nausea, vomiting, and digestive issues but can be easily managed. Also, weight loss drugs should be coupled with diet and lifestyle modifications to shed weight and reduce the overall risk of diseases associated with obesity," he added.
What are the healthiest ways to reverse obesity?
The classification of obesity can impact an individual's approach to treatment. While using injectables for weight loss can seem appealing due to their convenience, they often come with risks and side effects. The foundation of effective weight management lies in adopting a balanced diet and healthy lifestyle choices.
1. Eat a well-balanced diet
A well-rounded diet rich in whole grains, lean proteins, healthy fats, fruits, and vegetables can not only promote weight loss but also nourish the body. Portion control, understanding serving sizes and mindful eating can help individuals become more aware of their eating habits.
2. Stay physically active
Engaging in regular exercise, whether through structured workouts or simply finding ways to be active throughout the day, can significantly aid weight loss efforts. Regular physical activity also improves mood and energy levels.
3. Behavioural changes
Small behavioural changes such as setting realistic goals, tracking progress, and seeking social support can maximise the effect of your weight loss efforts. Stress management also plays a key role in weight management.
4. Stay consistent
Weight loss does not happen overnight. Continuous efforts can make it easier to sustain habits that support weight loss over the long term.
Additionally, surgical options, such as bariatric surgery, can be effective for certain individuals, however, they do not replace the need for lifestyle changes that support overall well-being.
"Obesity reversal is possible with diet and lifestyle modifications. However, it is a very demanding task involving eating right and exercising regularly without fail. Also, it is important to achieve these results sustainably," Dr. Gautam added.
Obesity is a complex condition which can be effectively addressed by focusing on nutritious eating, regular physical activity, and staying consistent. A holistic approach centred on healthy lifestyle choices can help individuals achieve sustainable results.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
9 hours ago
- The Print
‘Fat-shamers are now Ozempic-shamers' — new book takes on India's weight-loss obsession
It was a power-packed panel: Minister of State Jitendra Singh, actor Sharmila Tagore, and HT Media chairperson Shobhana Bhartia shared the stage alongside the two authors and Sanghvi. 'Will you be listed among the quacks – the dieticians and gym trainers who masquerade as weight-loss experts?' journalist and columnist Vir Sanghvi asked Mithal, half-jokingly. New Delhi: At the launch of leading endocrinologist Ambrish Mithal's book on obesity, co-authored with journalist Shivam Vij, the discussion turned to India's cultural obsession with weight loss and the science behind the drugs that have everyone in a chokehold. But the question that kicked off the event at Delhi's ITC Maurya last week captured both the uncertainty and the social media debates swirling around those promoting such drugs. Mithal and Vij's book — The Weight Loss Revolution: Weight Loss Drugs and How to Use Them, published by Juggernaut Books — describes itself as the authoritative work on Ozempic, Mounjaro and other GLP-1 drugs. Also read: Desperate Indians want Ozempic on prescription. Huge shift from traditional drugs, say doctors The science behind the 'revolution' While working on the book, Mithal sought to confront a hydra-headed demon: misinformation. The rise of GLP-1 drugs is linked to the increase in health-related conversation, media consumption, and a society in which being thin is the perennial aspiration. As a result, it's been written and talked about tremendously. 'The media either takes it to one extreme or another,' Mithal said. 'Nearly every two weeks, The New York Times has an article saying that this is the answer to the world's problems. Then there are those who say this is a marketing gimmick. As usual, the answer lies somewhere in between.' The book's genesis lay in Mithal's desire to explain the science behind what has been described as 'a revolution' in the weight loss world. Vij, Mithal's co-writer and first obesity patient to take semaglutide — the active ingredient in Ozempic and Wegovy — said he lost 15 kgs over the past 15 months. Now, the endocrinologist has one hundred patients on Wegovy, over 500 on Mounjaro (tirzepatide), and thousands on Rybelsus. These drugs were originally prescribed for diabetes. However, half of Mithal's patients want to use the drug to lose weight. 'Over the years, other than lifestyle changes and invasive bariatric surgery, all other methods to treat obesity have fallen off,' said Mithal. Also read: I was a pregnant penguin, see my before-after pics. 66-yr-old's Ozempic to Mounjaro journey Standing up to Ozempic-shamers GLP-1 drugs exist in a strange, inchoate space. There's covert acceptance, with leading celebrities taking Ozempic and the easy availability of the drug. But for the most part, there's reluctance in terms of public acknowledgment. Moreover, its usage is met with scepticism. As Vij noted, a layer of shame surrounds those who have taken it –– because they supposedly haven't 'put in the work.' 'Yesterday's fat-shamers are today's Ozempic-shamers,' he said. 'They're not happy either way. When you're fat, they're unhappy and when you're thin, they're unhappy.' The book features interviews with nine of Mithal's patients. One of them, a 26-year-old woman, gained weight after an accident at the age of 18. She was unable to lose weight through traditional methods. Other than delving into the science, the book also appears to lift some of the stigma around the drugs –– facilitating widespread, public acceptance. Actor Sharmila Tagore, who made it to the event via three modes of transport courtesy rain and the ensuing traffic, said that having spent her life in front of the camera, 'she understands society's obsession with bodies.' That's why this book comes at a critical time, as these drugs are projected to fundamentally alter this obsession. 'In a few years, everybody will be on it and everybody will be thin. That's my prediction,' said Vij. (Edited by Prashant)
Time of India
12 hours ago
- Time of India
What other health conditions are weight-loss drugs being used and tested for?
Bengaluru: Novo Nordisk 's weight-loss treatment Wegovy gained U.S. approval to treat a progressive liver condition on Friday, as the Danish drugmaker looks to boost sales and widen insurance coverage. Eli Lilly's blockbuster diabetes drug Mounjaro and related weight-loss therapy Zepbound, and Novo's rival medicines Ozempic and Wegovy brought in combined sales of over $40 billion last year, which is expected to rise to $60 billion in 2025. Here are some of the other conditions the drugs are being used and tested for: Alcohol addiction A study conducted by the University of Copenhagen's Psychiatric Centre Rigshospitalet is investigating whether semaglutide - the main ingredient in Wegovy and Ozempic - can help reduce alcohol intake in 108 patients diagnosed with alcohol use disorder and obesity . Alzheimer's disease Novo Nordisk is testing semaglutide in a late-stage trial in patients with early Alzheimer's disease. The study, which will enroll 1,840 patients, could have an initial data readout as early as later this year. Cardiovascular disease Eli Lilly was testing tirzepatide - the main ingredient in Mounjaro and Zepbound - for patients with heart failure and obesity. Lilly had said it would enroll about 700 people in the study, but the company said in May that it has withdrawn its U.S. application for heart failure approval. Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in overweight or obese adults without diabetes. The European Medicines Agency backed the use of Novo's semaglutide to help ease heart failure symptoms in people with obesity in September 2024. Chronic kidney disease Novo's Ozempic is approved in the United States for reducing the risk of kidney failure and disease progression as well as the risk of death due to heart problems in diabetes patients with chronic kidney disease. Lilly's tirzepatide is being evaluated in a mid-stage study of patients with chronic kidney disease and obesity. Lilly plans to enroll up to 140 participants with the study expected to be completed next year. Liver disease Novo's Wegovy in August became the first GLP-1 therapy approved in the U.S. to treat adults with metabolic dysfunction-associated steatohepatitis, or MASH, based on results from the first part of its late-stage trial. Results from the second part, with about 1,200 patients, is expected in 2029. Lilly's tirzepatide in February helped up to 74% of patients achieve absence of MASH with no worsening of liver scarring at 52 weeks, compared with 13% of patients on placebo, in a mid-stage trial. Neurological disorders Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new-onset idiopathic intracranial hypertension, a condition associated with obesity in which blood pressure inside the head rises. The study has enrolled about 50 patients and is expected to complete in October 2025. Sleep apnea Zepbound was approved by the U.S. Food and Drug Administration for obstructive sleep apnea in December 2024, making it the first drug to directly treat patients with the common disorder that causes breathing disruption while sleeping.
Time of India
a day ago
- Time of India
What is Ozempic Vulva, the little-known side effect of the popular weight loss drug women are talking about
You've likely heard of 'Ozempic face', 'Ozempic tongue', 'Ozempic feet', and 'Ozempic hands'. Here's a new addition: Ozempic vulva. Making its turn around the social media frequently now, Ozempic vulva isn't a medical diagnosis; rather, it's a label coined by women noticing unexpected changes in their vulva or vaginal area after using Ozempic or similar GLP-1 weight-loss drugs. Ozempic is a widely used weight-loss and diabetes medication, but some women taking it are reporting surprising and sensitive side effects. These changes include sagging skin, dryness, muscle weakness, loss of fullness, altered discharge, and even pelvic weakness. While it may sound surprising, experts say these shifts are often tied to rapid weight loss, hormone shifts, and hydration changes. What is Ozempic? Ozempic (semaglutide) is a well-known prescription drug that's used to treat the blood sugar of people with type 2 diabetes. Ozempic is given as an injection under your skin. Ozempic is also used to lower the risk of cardiovascular events (heart attack, stroke, or death) in people who have type 2 diabetes and heart disease. The Food and Drug Administration first approved the injectable medication for treating diabetes in 2017; the agency approved a drug with a higher dose of the active ingredient in Ozempic, called semaglutide, to treat obesity in 2021, under the brand name Wegovy. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Could Be the Best Time to Trade Gold in 5 Years IC Markets Learn More Undo Since then, talk of the drug has popped up across the internet. The prescription drug keeps gaining attention as celebrities, a tech mogul, and TikTok influencers have described taking it to lose weight in short time frames. What is Ozempic vulva? Known casually as 'Ozempic vulva' or 'Ozempic vagina', the issue refers to changes in the genital area linked to rapid weight loss. It's not an official medical term. Instead, it's a nickname women have coined to describe certain changes in the genital area while using GLP-1 medications like Ozempic, Wegovy, or Mounjaro. Though not formally acknowledged by drugmakers, more users are sharing what they notice, and experts are now paying attention. As reported by the NY Post, Dr. Sherry Ross, an OB-GYN in Santa Monica, CA, and author of 'She-ology' and 'She-ology, the She-quel,' told HealthCentral, '[The rapidity of] weight loss can cause visible skin sagging, laxity and wrinkles throughout the body,' adding, 'All areas of the body can show visible skin changes in response to this significant weight loss,' she added, 'including the lower belly, pubic mons, and inner and outer labia. ' Why does it happen and how? The vagina is surrounded by two sets of 'lips' or folds of skin. The labia majora are the outer, larger folds, while the labia minora are the inner, smaller folds. They extend from the mons pubis, the rounded, fatty area over the pubic bone. Some GLP-1 users have complained that their weight loss has led to a decrease in the volume of their labia majora, causing it to appear deflated or aged. Labia puffing may help. The procedure restores volume and fullness to the labia majora via dermal fillers or fat grafting. Experts point to a few key factors contributing to Ozempic vulva: Rapid weight loss: The fast reduction in body fat doesn't allow skin and soft tissues to adapt, leading to sagging or volume loss in areas like the labia and pubic mound. Muscle loss: Alongside fat loss, muscle mass, including pelvic floor muscles, can decrease. This may reduce support and sensation in the vulvovaginal area. Hormones and hydration: Less fat means less stored estrogen, which helps maintain vaginal moisture and tissue health. GI side effects like vomiting or diarrhea can cause dehydration, worsening dryness. Microbiome disruption: Since GLP-1 drugs slow digestion, they can alter gut bacteria. Because gut and vaginal microbes are linked, this may increase the risk of imbalances and infections As per the NY Post, Dr. Michael Tahery, a board-certified OB/GYN in LA, noted on his website that the fillers used in labia puffing are comparable to facial fillers. The tiny injections can last up to eight months a session and don't require recovery time. With fat grafts, a doctor injects a small amount of fat from the patient's thigh, abdomen, or elsewhere in their body into the labia. 'The benefit of this treatment is that it does not pose risks for rejection because it uses the patient's own fat,' Tahery wrote. 'The fat is easily reabsorbed by the body over time.' Labiaplasty to reshape the labia and vaginal tightening to restore firmness to the vaginal canal may also provide relief. Ozempic Vulva: Common complaints What happens due to the phenomenon of Ozempic vulva? Medical professionals have outlined three key issues associated with this phenomenon: Sagging or aged appearance of the labia: Rapid fat loss can diminish the padding in the outer labia and pubic area, causing a 'deflated,' wrinkled, or aged look. Pelvic weakness and vaginal looseness: GLP-1 medications don't just reduce fat; they can also lead to muscle loss, including in pelvic muscles. Women may feel reduced tone or looseness, impacting comfort and sexual experience. Dryness and vaginal irritation: Dehydration from GI side effects like nausea or diarrhea, along with hormone shifts that reduce natural lubrication, can lead to dryness and discomfort. Other related symptoms noted include changes in vaginal discharge, odor, and infections, as the gut-vagina microbial balance may be affected. Real women, real experiences As reported by The Sun, 30-year-old Paige Osprey noticed sagging of her labia after losing three stone (≈19 kg) with weight-loss injections like Ozempic. She even mentioned what she called a 'cameltoe' effect in tight clothing, a visibility she found distressing. The changes interfered with intimacy and self-esteem. As reported by The Sun, Paige opted for a labia puffing procedure using hyaluronic acid filler, which some call 'the other lip filler,' and says it restored volume and confidence, even renewing her sex life. What to do if you notice Ozempic vulva? First and foremost, consult your healthcare provider if you experience dryness, sagging, or discomfort. Second order of business: hydrate well, especially if you're dealing with gastrointestinal side effects. Consider supporting your pelvic floor health with exercises and moderating the pace of weight loss to give your body time to adapt. Topical solutions like lubricants, moisturizers, or probiotics can support vaginal health and balance microbiome risks. Besides, cosmetic or reconstructive options such as labia puffing (fillers or fat grafts) or labiaplasty are available. However, these should be approached carefully and discussed with a qualified provider. This article is for informational purposes only and does not constitute medical advice. 'Ozempic vulva' is an informal term and not a recognized medical diagnosis. Always consult a qualified healthcare provider before making any decisions about medications, side effects, or treatments. Inside Ozempic: Does the drug really help in weight loss and what are its possible side effects?
